Find a Product

Hydroxycarboxylic acid receptor 2 (HCA2)

Target Class
GPCR
Family
Hydroxycarboxylic acid
Official Symbol
GPR109A
Species
Human
Accession Number
NM_177551
Alias Names
HCAR2; NIC1; G protein-coupled receptor 109A; G protein-coupled receptor HM74a; G-protein coupled receptor 109A; G-protein coupled receptor HM74A; GPR109A; HCA2; HM74a; HM74b; NIACR1; PUMAG; Puma-g; hydroxy-carboxylic acid receptor 2; hydroxycarboxylic acid receptor 2; niacin receptor 1; nicotinic acid receptor
Background
Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5- methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.
+ Show More

Solution Portfolio

Related Family Members:

Hydroxycarboxylic acid
?

DiscoveRx offers cell-based assays that target other members of this gene family or functional group. Click on the family name to browse all available assays for that target family


Assay Readout ▲BackgroundSpeciesCell Line
cAMPCHO-K1Human95-0122C2
β-ArrestinCHO-K1Human93-0301C2
 
Assay Readout ▲BackgroundSpeciesAssay Kit
cAMPCHO-K1Human95-0122E2CP2S
cAMPCHO-K1Human95-0122E2CP2M
cAMPCHO-K1Human95-0122E2CP2L
β-ArrestinCHO-K1Human93-0301E2CP2S
β-ArrestinCHO-K1Human93-0301E2CP2M
β-ArrestinCHO-K1Human93-0301E2CP2L
 
KINOMEscan TKscan BROMOscan NHRscan GPCRscan PATHscan
        Available  
The DiscoveRx Advantage:
Access your Target with Three Signaling Platforms